Related references
Note: Only part of the references are listed.Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs
Domenico Pastore et al.
ANNALS OF HEMATOLOGY (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prophylactic Antiemetics for Haematological Malignancies: Prospective Nationwide Survey Subset Analysis in Japan
Isao Yoshida et al.
IN VIVO (2019)
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial
Amber B. Clemmons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Lawrence H. Einhorn et al.
SUPPORTIVE CARE IN CANCER (2017)
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy
Jorn Herrstedt et al.
SUPPORTIVE CARE IN CANCER (2017)
NCCN Guidelines® Insights Antiemesis, Version 2.2017 Featured Updates to the NCCN Guidelines
Michael J. Berger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial
Se-Il Go et al.
ONCOLOGIST (2017)
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2017)
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2014)
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
Lee Schwartzberg et al.
SUPPORTIVE CARE IN CANCER (2014)
Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study
Saroj Vadhan-Raj et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
I. N. Olver et al.
SUPPORTIVE CARE IN CANCER (2013)
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
Costantine Albany et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Nicola Di Renzo et al.
SUPPORTIVE CARE IN CANCER (2011)
Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: The MASCC antiemesis tool
Alexander Molassiotis et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2007)
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin -: Analysis of combined data from two Phase III randomized clinical trials
RJ Gralla et al.
CANCER (2005)
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall
AR Martin et al.
SUPPORTIVE CARE IN CANCER (2003)
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
WH Wilson et al.
BLOOD (2002)
Share Paper
